GlobeNewswire: Clinuvel Pharmaceuticals Limited Contains the last 10 of 29 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:06:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853764/0/en/Photomedicine-Pioneer-CLINUVEL-Unveils-Clinical-Cosmetic-Ambitions-to-German-Investors.html?f=22&fvtc=4&fvtv=29086Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors2024-03-28T08:25:58Z<![CDATA[DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine.]]>https://www.globenewswire.com/news-release/2024/03/05/2840064/0/en/Malibu-shines-a-light-on-CLINUVEL-s-pioneering-work-in-photomedicine.html?f=22&fvtc=4&fvtv=29086Malibu shines a light on CLINUVEL’s pioneering work in photomedicine2024-03-05T02:38:26Z<![CDATA[MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky.]]>https://www.globenewswire.com/news-release/2023/02/28/2617764/0/en/CLINUVEL-Launches-CYAC%C3%8ALLE-Next-Generation-Solar-Care.html?f=22&fvtc=4&fvtv=29086CLINUVEL Launches CYACÊLLE, Next Generation Solar Care2023-02-28T23:58:37Z<![CDATA[UV, HEV protection for individuals at high risk of photoageing and skin cancer]]>CLINUVEL today launched CYACÊLLE, a next generation of polychromatic solar care. CYACÊLLE is designed to protect skin from a wide spectrum of damaging solar radiation under extreme conditions.CLINUVEL's CYACÊLLECLINUVEL's CYACÊLLE has been formulated for individuals at high risk of photodamage.CYACELLEEnergy waves within the solar spectrum which reach the Earth’s surface. Ultraviolet radiation has the wavelength range of 190-400 nm; visible light has the wavelength range of 400-700 nm (including HEV from 400-500nm); and infrared radiation has the wavelength of 700-1,000 nm.Light across the solar spectrumhttps://www.globenewswire.com/news-release/2023/02/23/2614910/0/en/Global-SCENESSE-demand-drives-increased-CLINUVEL-revenues-earnings.html?f=22&fvtc=4&fvtv=29086Global SCENESSE® demand drives increased CLINUVEL revenues, earnings2023-02-23T23:14:16Z<![CDATA[MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summaryPositive Results in the Half Year to 31 December 2022]]>CLINUVEL Group financial performance for the half year ended 30 December, since first commercial sales.CLINUVEL Financial Performancehttps://www.globenewswire.com/news-release/2023/02/02/2600084/0/en/CLINUVEL-Drug-Significantly-Reduces-Critical-UV-Skin-Damage-in-Fair-Skinned-Individuals.html?f=22&fvtc=4&fvtv=29086CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals2023-02-02T00:14:01Z<![CDATA[Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused by ultraviolet radiation Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused by ultraviolet radiation]]>https://www.globenewswire.com/news-release/2023/01/15/2588924/0/en/CLINUVEL-Trial-Results-Show-Drug-Reduces-DNA-Damage.html?f=22&fvtc=4&fvtv=29086CLINUVEL Trial Results Show Drug Reduces DNA Damage2023-01-15T23:23:50Z<![CDATA[Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer]]>https://www.globenewswire.com/news-release/2022/05/10/2439189/0/en/CLINUVEL-progresses-vitiligo-treatment-program.html?f=22&fvtc=4&fvtv=29086CLINUVEL progresses vitiligo treatment program2022-05-10T01:33:06Z<![CDATA[Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide]]>Initial clinical studies of afamelanotide showed the drug could repigment skin. This patient received four afamelanotide implants and NB-UVB light therapy over six months, largely repigmenting lesions on their eyelids. Images taken at days 0 and 171 of CUV102 study, courtesy of the study investigator.Vitiligo repigmentation in CLINUVEL's CUV102 studyhttps://www.globenewswire.com/news-release/2022/05/04/2435187/0/en/Positive-final-results-in-stroke.html?f=22&fvtc=4&fvtv=29086Positive final results in stroke2022-05-04T00:24:35Z<![CDATA[World-first stroke study CUV801 evaluating afamelanotide World-first stroke study CUV801 evaluating afamelanotide]]>Individual patient data of brain scans (MRI-FLAIR) showing a reduction of the affected area in five of the six patients treated in CUV801.Figure 1 - CUV801 MRI-FLAIR resultsIndividual NIHSS scores in five of six patients treated in the CUV801 study showed improvement in neurological functions. Two patients were symptom free at day 42.Figure 2 - CUV801 NIHSS resultshttps://www.globenewswire.com/news-release/2022/04/29/2432159/0/en/Letter-to-shareholders-from-CLINUVEL-s-CEO.html?f=22&fvtc=4&fvtv=29086Letter to shareholders from CLINUVEL’s CEO2022-04-29T05:20:54Z<![CDATA[LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Dear shareholders, friends,]]>https://www.globenewswire.com/news-release/2021/11/08/2328862/0/en/CLINUVEL-Expands-Pharmaceutical-Portfolio.html?f=22&fvtc=4&fvtv=29086CLINUVEL Expands Pharmaceutical Portfolio2021-11-08T04:03:32Z<![CDATA[Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders]]>